Moderna Inc.
said Thursday it had net income of $1.465 billion, or $3.61 a share, in the fourth quarter, down from $4.868 billion, or $11.29 a share, in the year-earlier period. Revenue fell to $5.084 billion from $7.211 billion a year ago. The FactSet consensus was for EPS of $4.60 and revenue of $5.017 billion. The decline in sales was mostly due to a steep fall in sales of the company’s COVID vaccines. Product sales fell 30% to $4.9 billion, due to lower sales volume and lower demand vs. the prior year.
said Thursday it had net income of $1.465 billion, or $3.61 a share, in the fourth quarter, down from $4.868 billion, or $11.29 a share, in the year-earlier period. Revenue fell to $5.084 billion from $7.211 billion a year ago. The FactSet consensus was for EPS of $4.60 and revenue of $5.017 billion. The decline in sales was mostly due to a steep fall in sales of the company’s COVID vaccines. Product sales fell 30% to $4.9 billion, due to lower sales volume and lower demand vs. the prior year.